Galmed Pharmaceuticals Ltd. (GLMD)

NASDAQ: GLMD · Real-Time Price · USD

1.190

-0.070 (-5.56%)

At close: May 16, 2025, 4:00 PM

1.230

+0.040 (3.36%)

After-hours: May 16, 2025, 7:45 PM EDT

Galmed Pharmaceuticals Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	2015 - 2019
Period Ending	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020	2015 - 2019
Selling, General & Admin	3.3	3.92	4.66	5.66	4.13	Upgrade
Research & Development	2.98	3.57	13	27.22	26.08	Upgrade
Operating Expenses	6.28	7.49	17.65	32.88	30.21	Upgrade
Operating Income	-6.28	-7.49	-17.65	-32.88	-30.21	Upgrade
Interest Expense	-0.61	-	-	-	-	Upgrade
Interest & Investment Income	0.5	0.38	0.3	0.56	1.19	Upgrade
Currency Exchange Gain (Loss)	0.04	-0.04	0.04	-0.03	-0.12	Upgrade
Other Non Operating Income (Expenses)	-0.02	0.25	-0.02	-0.04	-0.03	Upgrade
EBT Excluding Unusual Items	-6.36	-6.9	-17.34	-32.39	-29.17	Upgrade
Gain (Loss) on Sale of Investments	-1.16	-0.01	-0.53	-0.08	0.4	Upgrade
Pretax Income	-7.52	-6.91	-17.87	-32.47	-28.77	Upgrade
Net Income	-7.52	-6.91	-17.87	-32.47	-28.77	Upgrade
Net Income to Common	-7.52	-6.91	-17.87	-32.47	-28.77	Upgrade
Shares Outstanding (Basic)	1	0	0	0	0	Upgrade
Shares Outstanding (Diluted)	1	0	0	0	0	Upgrade
Shares Change (YoY)	303.31%	65.23%	2.22%	15.59%	0.79%	Upgrade
EPS (Basic)	-8.08	-29.95	-127.90	-237.59	-243.35	Upgrade
EPS (Diluted)	-8.08	-29.95	-127.90	-237.59	-243.35	Upgrade
Free Cash Flow	-5.88	-6.14	-18.51	-32.9	-26.33	Upgrade
Free Cash Flow Per Share	-6.32	-26.59	-132.48	-240.78	-222.72	Upgrade
EBITDA	-6.2	-7.46	-17.62	-32.84	-30.17	Upgrade
D&A For EBITDA	0.08	0.03	0.04	0.04	0.04	Upgrade
EBIT	-6.28	-7.49	-17.65	-32.88	-30.21	Upgrade

Updated Nov 14, 2024. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q